Abstract
The aim of our study was to demonstrate that saliva can be used as an effective material for SARS-CoV-2 testing and screening of large population groups to identify Covid-19 clusters.
The most important aspect of saliva sampling approach is the convenience of obtaining material by self-sampling that is even possible at home.
In our experiments, saliva was sufficiently stable for testing for at least 24 hours after collection.
The results obtained from the saliva of a SARS-CoV-2 positive patient were consistent with those obtained from nasopharyngeal and oropharyngeal swabs from the same patient with the sensitivity 90% and specificity 100% during the first two weeks after the onset of symptoms.
To demonstrate the usefulness of testing saliva material for mass screening, crowd sampling with pooling was performed on 3660 people in 3-day time (44 samples were tested positive).
We conclude that saliva testing is an appropriate tool for screening campaigns and cluster detection, that is able to detect more infected people in a shorter period of time with little human resources and thus help to stop the epidemic spread more quickly.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Ministry of Education and Science, Republic of Latvia. Funding number: VPP-COVID-2020/1-0008. Additional funding was provided by E.Gulbja laboratory.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by Ethics Committee of Pauls Stradins Clinical university hospital (record No 300720-18L).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data generated or analysed during this study are included in this published article.
